Biotech ETFs that track smaller biotech companies also got the worst of the selling. Since June 6, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), which tracks potential up-and-coming biotechnology companies that are in the clinical trials stage, fell 14.4%. The ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials, declined 12.2%.
BBC includes a 1.3% in IMGN. SBIO holds 0.07% in INFI.
Meanwhile, other segments of the healthcare industry have held up over the same period. For instance, the iShares U.S. Healthcare Providers ETF (NYSEArca: IHF), which follows companies that provide health insurance, diagnostics and specialized treatments, dipped 0.6% and the broader First Trust Health Care AlphaDEX Fund (NYSEArca: FXH), which tracks a smart-beta health care sector indexing methodology, dropped 1.0%.
For more information on the biotech sector, visit our biotechnology category.
iShares Nasdaq Biotechnology ETF